The role of interleukin‐36 in health and disease states

Abstract

The interleukin (IL)‐1 superfamily upregulates immune responses and maintains homeostasis between the innate and adaptive immune systems. Within the IL‐1 superfamily, IL‐36 plays a pivotal role in both innate and adaptive immune responses. Of the four IL‐36 isoforms, three have agonist activity (IL‐36α, IL‐36β, IL‐36γ) and the fourth has antagonist activity (IL‐36 receptor antagonist [IL‐36Ra]). All IL‐36 isoforms bind to the IL‐36 receptor (IL‐36R). Binding of IL‐36α/β/γ to the IL‐36R recruits the IL‐1 receptor accessory protein (IL‐1RAcP) and activates downstream signalling pathways mediated by nuclear transcription factor kappa B and mitogen‐activated protein kinase signalling pathways. Antagonist binding of IL‐36Ra to IL‐36R inhibits recruitment of IL‐1RAcP, blocking downstream signalling pathways. Changes in the balance within the IL‐36 cytokine family can lead to uncontrolled inflammatory responses throughout the body. As such, IL‐36 has been implicated in numerous inflammatory diseases, notably a type of pustular psoriasis called generalized pustular psoriasis (GPP), a chronic, rare, potentially life‐threatening, multisystemic skin disease characterised by recurrent fever and extensive sterile pustules. In GPP, IL‐36 is central to disease pathogenesis, and the prevention of IL‐36‐mediated signalling can improve clinical outcomes. In this review, we summarize the literature describing the biological functions of the IL‐36 pathway. We also consider the evidence for uncontrolled activation of the IL‐36 pathway in a wide range of skin (e.g., plaque psoriasis, pustular psoriasis, hidradenitis suppurativa, acne, Netherton syndrome, atopic dermatitis and pyoderma gangrenosum), lung (e.g., idiopathic pulmonary fibrosis), gut (e.g., intestinal fibrosis, inflammatory bowel disease and Hirschsprung's disease), kidney (e.g., renal tubulointerstitial lesions) and infectious diseases caused by a variety of pathogens (e.g., COVID‐19; Mycobacterium tuberculosis, Pseudomonas aeruginosa, Streptococcus pneumoniae infections), as well as in cancer. We also consider how targeting the IL‐36 signalling pathway could be used in treating inflammatory disease states.